BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37516994)

  • 1. [Aggressive pituitary adenoma and pituitary carcinoma].
    Tóth M
    Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
    Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
    Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
    Raverot G; Burman P; McCormack A; Heaney A; Petersenn S; Popovic V; Trouillas J; Dekkers OM;
    Eur J Endocrinol; 2018 Jan; 178(1):G1-G24. PubMed ID: 29046323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
    Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
    J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive Pituitary Adenomas and Carcinomas.
    Ilie MD; Jouanneau E; Raverot G
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive pituitary tumours and pituitary carcinomas.
    Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
    Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early recognition of aggressive pituitary adenomas: a single-centre experience.
    Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
    Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
    Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive pituitary tumors (PitNETs).
    Nishioka H
    Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
    Hirohata T; Ishii Y; Matsuno A
    Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options].
    Maïza JC; Caron P
    Ann Endocrinol (Paris); 2009 Sep; 70 Suppl 1():S12-9. PubMed ID: 19878763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive pituitary adenomas--diagnosis and emerging treatments.
    Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
    Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
    Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
    Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Therapy of Aggressive Pituitary Tumors.
    Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
    Touma W; Hoostal S; Peterson RA; Wiernik A; SantaCruz KS; Lou E
    J Clin Neurosci; 2017 Jul; 41():75-77. PubMed ID: 28291643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
    Dutta P; Reddy KS; Rai A; Madugundu AK; Solanki HS; Bhansali A; Radotra BD; Kumar N; Collier D; Iacovazzo D; Gupta P; Raja R; Gowda H; Pandey A; Devgun JS; Korbonits M
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3539-3544. PubMed ID: 31125088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.
    Cooper O; Bonert V; Liu NA; Mamelak AN
    Front Endocrinol (Lausanne); 2021; 12():725014. PubMed ID: 34867776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition and diagnosis of aggressive pituitary tumors.
    Kasuki L; Raverot G
    Rev Endocr Metab Disord; 2020 Jun; 21(2):203-208. PubMed ID: 31808044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
    Lenders N; McCormack A
    Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.